Research programme: ATIC homodimerization inhibitors - Curve Therapeutics
Latest Information Update: 17 May 2024
At a glance
- Originator Curve Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Aminoimidazolecarboxamide ribonucleotide formyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 25 Apr 2024 Early research in Cancer in United Kingdom (unspecified route) prior to April 2024 (Curve Therapeutics pipeline, April 2024)